Small Molecule Licensing Deal Benchmarks

Small molecules remain the most frequently transacted modality in biopharma licensing. Phase 2 small molecule deals carry a median total deal value of $1.6B, with upfront payments ranging from $144M to $401M. While biologics have captured headlines, small molecules continue to dominate deal volume due to established manufacturing, oral bioavailability, and favorable cost of goods.

Milestone structures in small molecule deals reflect a mature transactional landscape. Development milestones average $345M, regulatory milestones contribute $552M, and commercial milestones reach $483M. The recommended split of 16% upfront and 84% milestones aligns with established market norms.

Royalty rates for small molecule out-licensing range from 11.8% to 19.3%, with tiered escalation to 23.3%. Competition from generic entry at patent expiry is factored into royalty term negotiations, making intellectual property strength and lifecycle management key valuation drivers.